Sana Biotechnology, Inc.
For the period ended Dec 31, 2025. Filed Mar 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 3, 2026
SANA$2.47+4.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except per share amounts)
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $71,870 | $127,566 |
| Marketable securities | 66,512 | 24,931 |
| Restricted cash | 4,195 | 3,832 |
| Prepaid expenses and other current assets | 6,099 | 4,479 |
| Total current assets | 148,676 | 160,808 |
| Property and equipment, net | 26,906 | 77,308 |
| Operating lease right-of-use assets | 38,313 | 57,961 |
| Intangible asset | 59,195 | 59,195 |
| Goodwill | 140,627 | 140,627 |
| Other non-current assets | 3,173 | 5,121 |
| TOTAL ASSETS | $416,890 | $501,020 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $1,669 | $5,210 |
| Accrued compensation | 13,240 | 14,449 |
| Accrued expenses and other current liabilities | 8,679 | 13,240 |
| Operating lease liabilities | 14,938 | 12,534 |
| Contingent consideration | 40,200 | - |
| Total current liabilities | 78,726 | 45,433 |
| Operating lease liabilities, net of current portion | 63,924 | 81,663 |
| Contingent consideration, net of current portion | 83,518 | 108,968 |
| Success payment liabilities | 19,238 | 4,556 |
| Other non-current liabilities | 10,600 | 9,896 |
| Total liabilities | 256,006 | 250,516 |
| Commitments and contingencies (Note 10) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.0001 par value; 50,000 shares authorized; zero shares issued and outstanding as of December 31, 2025 and December 31, 2024 | - | - |
| Common stock, $0.0001 par value; 750,000 shares authorized; 266,732 and 223,923 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 27 | 22 |
| Additional paid-in capital | 2,009,845 | 1,855,318 |
| Accumulated other comprehensive income | 28 | 14 |
| Accumulated deficit | (1,849,016) | (1,604,850) |
| Total stockholders' equity | 160,884 | 250,504 |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $416,890 | $501,020 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.